Glycemic Control in Patients with Type 2 Diabetes
Metadata[+] Show full item record
There is no clearly superior oral agent for glycemic control in patients with type 2 diabetes. (Strength of Recommendation [SOR]: C) Metformin (Glucophage) has shown additional benefit when compared with other treatments (including insulin) for diabetes-related outcomes and all-cause mortality and should be considered the agent of choice for initial monotherapy, particularly in obese patients. (SOR: A)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.